welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Upcoming events – pivotal data loom for Novavax and Mallinckrodt
Welcome to your weekly digest of approaching regulatory and clinical readouts. Novavax is up 4% today thanks to topline results from a phase II trial showing that its Nanoflu influenza vaccine caused “vigorous immune responses” to four strains of flu, and that these responses were enhanced when the group’s Matrix-M adjuvant was added to the vaccine.
But an even more meaningful event is approaching. Novavax’s lead asset, a vaccine against respiratory syncytial virus, is in phase III, and after its disastrous failure two years ago in a study that was intended to be pivotal this is its last chance.
Resvax, also known as RSV F Vaccine since it targets the fusion protein of the virus, crashed out of the Resolve trial, testing it in prevention of moderate to severe RSV-associated lower respiratory tract disease, in mid-2016.
expertly curated content related to this topic
-
Risk-Reducing Surgery in FAP: Role for Surgeons Beyond the IncisionBACKGROUND : Although primary therapy in...
-
Protein-losing enteropathy in a patient with familial adenomatous polyposis and advanced colon cancerAbstract A 29-year-old female visited...
-
French Digestive Polyposis CohorteFrench cohorte about polyposis digestive...
-
Dual Focus NBI and pCLE in FAP Related Duodenal AdenomaBackground: Familial adenomatous pol...
-
Screening and Surveillance of the Early Detection of Colorectal Cancer and Adenomatous PolypsIn the United States, colorectal cancer ...
-
Desmoid Tumours: Our Experience of Six Cases and Review of LiteratureDesmoid tumours represent aggressive fib...
-
Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP)Background and study aim The relative ri...